Hologic Inc. (NASDAQ:HOLX) does about 2.46M shares in volume on a normal day but saw 2633957 shares change hands in Tuesday trading. The company now has a market cap of 15.63B USD and an enterprise value of about $18.04B. Its current market price is $59.22, marking a decrease of -0.84% compared to the previous close of $59.72. The 52 week high reached by this stock is $73.63 whilst the lowest price level in 52 weeks is $26.49. The script in recent trading has seen the stock touch a high of $60.51 and a low of $58.40.
Hologic Inc. (HOLX) has a 20-day trading average at $66.08 and the current price is -19.57% off the 52-week high compared with 123.56% distance from its 52-week low. The 50-day simple moving average of the closing price is $62.63 and its 200-day simple moving average is $52.22. If we look at the stock’s price movements over the week, volatility stands at 3.96%, which decreases to 3.02% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 32.83 to suggest the stock is neutral.
18 analysts observing the Hologic Inc. (HOLX) stock have set the 12-month price targets for the company’s shares at between $68.00 and $84.00. The consensus objective for the share price is $77.73, suggesting that the stock has a potential upside of 23.81% over the period. The median price target is 24.08% away from the current levels at $78.00.
FactSet Research has provided data showing that 18 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 12 analysts have rated it as a buy and 5 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 30, 2020 when Cowen upgraded the stock to “Outperform” and issued a price target of $64. Raymond James also upgraded the stock to “Outperform” from Mkt Perform on June 03, 2020 at a price target of $62. SVB Leerink upgraded its price target at $62.
The current price level is -11.25%, -5.32%, and 13.55% away from its SMA20, SMA50, and SMA200 respectively, with the HOLX price moving above the 50-day SMA on September 01. Hologic Inc. (HOLX) stock is down -10.43% over the week and -16.97% over the past month. Its price is 13.43% year-to-date and 22.20% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $0.75 above consensus estimates by $0.37. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at $1.05 and $2.98 for whole year. HOLX’s earnings per share are forecast to grow by 22.60% this year and 39.90% over next year. Expected sales for next quarter are $1.1 billion, which analysts say will come at $3.43 billion for the current fiscal year and next year at $4.2 billion. In addition, estimates put the company’s current quarterly revenue at an average of $989 million.
Its 12-month price target is $78.00. To reach the target analysts have set, the stock logically needs to grow 23.81 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $68.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $84.00.
Outstanding shares total 259.87M with insiders holding 0.33% of the shares and institutional holders owning 99.57% of the company’s common stock. The company has a return on investment of -1.30% and return on equity of 22.80%. The price to earnings ratio (P/E ratio) amounts to 31.75 while the forward price to earnings ratio is 14.13. The beta has a value of 1.43. Price to book ratio is 6.82 and price to sales ratio is 4.74.
According to a U.S. Securities and Exchange Commission filing, T Rowe Price Mid Cap Growth Fund has added its position in Hologic Inc. (HOLX) to 13,500,000 shares, mirroring a recent increase by 0.07%. T Rowe Price Mid Cap Growth Fund added 9800.0 shares of Hologic Inc. common stock bringing its total worth to about $942.03 million at the end of recent close, SEC documents show. T Rowe Price Mid Cap Growth Fund isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which sold off 36915.0 shares to end up with 7,330,009 shares worth $511.49 million. Vanguard Mid Cap Index Fund cut their holdings by -0.76% in the company over the course of the most recent quarter. It now holds a 2.45% position in Hologic Inc. thanks to 6.34 million shares amounting to $442.23 million.